GE HealthCare initiated with a Neutral at UBS

UBS analyst Graham Doyle initiated coverage of GE HealthCare Technologies with a Neutral rating and $86 price target. The analyst says the company’s near-term earnings momentum is offset by the firm’s lower optimism on its mid-term margin expansion and a "relatively full" stock valuation. GE HealthCare is "just not cheap enough," the analyst tells investors in a research note.